{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:05:12Z","timestamp":1780506312022,"version":"3.54.1"},"reference-count":103,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The rapid development of novel agents and combinations in chronic lymphocytic leukemia\/small lymphocytic lymphoma has led to multiple options for frontline therapy and relapse, including continuous therapy and fixed duration regimens. The choice of therapy may be affected by the patient performance status, molecular abnormalities, potential side effects, logistics, patient expectations, and sequencing options in patients who will likely need more than one therapy in their lifetime. Current therapy options consist of several Bruton tyrosine kinase inhibitors (BTKis; covalent and noncovalent), one BCL-2 inhibitor (with others in development), and antibodies, with the possibility of single-agent therapy, doublets, or, less frequently, triplet therapy. In addition, treatment for double-refractory patients (refractory to both a BTKi and a BCL-2i) is available, but options are limited, so additional therapies for treatment in these high-risk patients are needed and in development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-517476","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:59:32Z","timestamp":1779998372000},"source":"Crossref","is-referenced-by-count":0,"title":["Chronic Lymphocytic Leukemia Through the Spectrum: Frontline Therapy, Sequencing With Subsequent Therapy, and Treatment of Double-Refractory Patients"],"prefix":"10.1200","volume":"46","author":[{"given":"Anna Maria","family":"Frustaci","sequence":"first","affiliation":[{"name":"ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Department of Hematology, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Department of Hematology, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F.","family":"vom Stein","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine and Medical Faculty, University of Cologne, Center for Integrated Oncology Aachen Bonn K\u00f6ln D\u00fcsseldorf, Center of Excellence on \u201cCellular Stress Responses in Aging-Associated Diseases\u201d, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine and Medical Faculty, University of Cologne, Center for Integrated Oncology Aachen Bonn K\u00f6ln D\u00fcsseldorf, Center of Excellence on \u201cCellular Stress Responses in Aging-Associated Diseases\u201d, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0012"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028205"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279012"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021959"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00144-4"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024476"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02265"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2129"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00196-7"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"F\u00fcrstenau M Robrecht S Von Tresckow J: The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-cd20-antibody combinations and chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia: Final analysis from the phase 3 GAIA\/CLL13 trial in Paper presented at: 30th Annual Meeting of the European Hematology Association. Milan 2025","DOI":"10.1002\/hon.70093_70"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024631"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004326"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Niemann CU Munir T Owen C: First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): Glow study 64-Month Follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis. Paper presented at: 66th Annual Meeting of the. San Diego CA American Society of Hematology 2024","DOI":"10.1182\/blood-2024-203269"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_71"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409804"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2515458"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Ghia P Wierda GW Barr PM: Relapse after first-line fixed duration ibrutinib + venetoclax: High response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma with up to 5 years of Follow-Up in the phase 2 CAPTIVATE study in Paper presented at: 65th Annual Meeting of the. San Diego CA American Society of Hematology 2023","DOI":"10.1182\/blood-2023-187128"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00758"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504341"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02503"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Soumerai JD Dogan A Seshan V: Multicenter phase II trial of zanubrutinib obinutuzumab and venetoclax (BOVen) in treatment-na\u00efve chronic lymphocytic leukemia: 5-year follow up retreatment outcomes and impact of MRD kinetics (\u0394MRD400) in Paper presented at: 66th Annual Meeting of the. San Diego CA American Society of Hematology 2024","DOI":"10.1182\/blood-2024-205697"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028899"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101538"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028550"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70166"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.263715"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2005943"},{"key":"e_1_3_2_30_2","unstructured":"Moreno C Munir T Owen C: First-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): Up to 5 years\u2019 Follow-up from the GLOW study in Paper presented at: 65th Annual Meeting of the. San Diego CA American Society of Hematology 2023"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189711"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0456"},{"key":"e_1_3_2_33_2","unstructured":"Cramer P Al-Sawaf O Goergen E: CLL18\/MOIRAI: An international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL\/SLL in Paper presented at: 30th Annual Meeting of the European Hematology Association. Milan 2025"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Wierda WG Jacobs R Barr PM: Consistently high 5.5-year progression-free survival (PFS) rates in patients with and without bulky baseline lymphadenopathy \u22655 cm are associated with high undetectable minimal residual disease (uMRD4) rates after first-line treatment with fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study in Paper presented at: 66th Annual Meeting of the. San Diego CA American Society of Hematology 2024","DOI":"10.1182\/blood-2024-200936"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02477"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024667"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101268"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1517972"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104408"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3934"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02662-y"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15613"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26595"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32100543"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70246"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02380"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213093"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01845-9"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00948"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820910"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4890"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02267-x"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02329-y"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1119"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019634"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-870238"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.251488"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27546"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70100"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025525"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007812"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015180"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011307"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00320-9"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00070-6"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011327"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2310144"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30414-5"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2137"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00166"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3815"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065802"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022861"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005083"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016006"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007708"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01181"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26682"},{"key":"e_1_3_2_89_2","first-page":"62","article-title":"Pirtobrutinib preclinical characterization: A highly selective, non-covalent (reversible) BTK inhibitor","volume":"142","author":"Gomez EB","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, et al: Pirtobrutinib preclinical characterization: A highly selective, non-covalent (reversible) BTK inhibitor. Blood 142:62-72, 2023","journal-title":"Blood"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011895"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147473"},{"key":"e_1_3_2_95_2","doi-asserted-by":"crossref","unstructured":"Omer Z Danilov A Forconi F et al: NX-5948) a novel Bruton\u2019s tyrosine kinase (BTK) degrader demonstrates rapid and durable clinical responses in relapsed\/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing phase 1a\/b trial. in Paper presented at: 67th Annual Meeting of the. Orlando FL American Society of Hematology 2025","DOI":"10.1016\/S2152-2650(25)00676-7"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971772.24358.c2"},{"key":"e_1_3_2_97_2","doi-asserted-by":"crossref","unstructured":"Ahn I Parrondo R Thompson M et al: Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB16673 in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) from the ongoing phase 1 CaDAnCe-101 study. in Paper presented at: 67th Annual Meeting of the. Orlando FL American Society of Hematology 2025","DOI":"10.1182\/blood-2025-85"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-826008"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003726"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002184"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001956"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.06.002"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-517476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:16:47Z","timestamp":1780503407000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-517476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-517476"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-517476","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e517476"}}